BioSpace News Archive

Mydecine Innovations Group today announced in preparation for its FDA pre-Investigational New Drug (IND) meeting on February 28th, the company has submitted a pre-IND briefing package to the U.S. Food and Drug Administration (FDA) for a clinical study evaluating MYCO-001 in a structured smoking cessation treatment program.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced positive topline results from Cohort 3 of REDWOOD-HCM.

Glycotope GmbH and CantonBio Deutschland GmbH announced the successful completion of CantonBio’s acquisition of Glycotope’s service business under the newly formed FyoniBio GmbH.

MaxCyte, Inc., a leading provider of enabling platform technologies for ex-vivo cell engineering, announces the signing of a strategic platform license with Intima Bioscience, Inc., a clinical stage biotechnology company developing genetically engineered cell therapies for solid tumor cancer.

Twist Bioscience Corporation and Abcam announced a licensing agreement under which Abcam will use a proprietary Twist VHH phage library for antibody discovery, development and commercialization for diagnostic and research applications.

Azafaros B.V. announced that the US Food and Drug Administration has granted Orphan Drug Designation for AZ-3102, a novel oral small molecule, in GM2 gangliosidosis including both Sandhoff and Tay-Sachs diseases.

Reviva Pharmaceuticals Holdings, Inc. announced that the first patients have been dosed in a pivotal Phase 3 study and long-term safety trial to assess Reviva’s new chemical entity brilaroxazine for the treatment of subjects with an acute exacerbation of schizophrenia.

Engage Technologies Group, Inc. has announced Zi Tang as its new Senior Vice President of Strategy & Operations.

ImmuneID today announced the appointment of Jeremiah Degenhardt, Ph.D., as Senior Vice President, Computational Biology.

BeiGene today announced the appointment of Margaret Dugan, M.D., and Alessandro Riva, M.D., to its Board of Directors.